Jessica Tang, PhD

Title(s)Postdoctoral Scholar, Dermatology
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, Santa Barbara, Santa Barbara, CABA06/2011Biology
    Indiana University, Bloomington, INMS05/2013Microbiology
    Indiana University, Bloomington, INPhD06/2018Physiology
    Collapse Awards and Honors
    Indiana Clinical and Translational Sciences Institute2013  - 2015Pre-doctoral training grant
    Indiana University School of Medicine2014Paul M. Harmon Award
    Indiana University School of Medicine2016  - 2018Doane and Eunice Dahl Wright Memorial Fellowship

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Pulliam N., Tang J., Nephew KP.In: Xiaoting Zhang, editor. Cancer Drug Discovery, Development. New York: Humana Press. Estrogen receptor regulation of microRNAs in breast cancer. 2018.
    2. Tang J, Pulliam N., Özes A, Buechlein A., Ding N., Keer H., Rusch D., O’Hagan H., Stack M., Nephew KP.Epigenetic targeting of adipocytes inhibits high-grade serous ovarian cancer cell migration and invasion. Molecular Cancer Research. 2018; 8(16):1226-1240 .
    3. Pulliam N., Fang F., Özes A., Tang J., Adewuyi A., Keer H., Lyons J., Baylin S., Matei D., Nakshatri H., Rassool F., Miller K., Nephew KP.Clin Cancer Res. An effective epigenetic-PARP inhibitor combination therapy for ovarian and breast cancers independent of BRCA-mutations. 2018; 13(24):3163-3175.
    4. Özes A, Pulliam N., Tang J., Yilm az Ö., Ertosun G, Matei D, Özes O., Nephew KP.Oncogene. Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity. 2018; 26(37):3589-3600.
    5. Tang J, Oroudjev E, Wilson L, Ayoub G.Integr Cancer Sci and Therap. Delphinidin and cyanidin exhibit antiproliferative and apoptotic effects in MCF7 human breast cancer cells. 2015; 1(2):82-86.
    6. Fang F*, Munck J*, Tang J*, Taverna P, Wang Y, Miller DF, Pilrose J, Choy G, Azab M, Pawelczak KS, VanderVere-Carozza P, Wagner M, Lyons J, Matei D, Turchi JJ, and Nephew KP (*Equal contribution).Clin Cancer Res. The novel, small molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. 2014; 24(20):6504-6516.
    7. Tang J, Fang F, Miller D, Pilrose J, Matei D, Huang T, Nephew KP.In: Verma M, editor. Cancer Epigenetics: Risk Assessment, Diagnosis, Treatment, and Prognosis. New York: Humana Press. Global DNA methylation profiling technologies and the ovarian cancer methylome. 2014.
    8. Lee CJ, Wilson L, Jordan MA, Nguyen V, Tang J, Smiyun G.Phytother Res. Hesperidin suppressed proliferations of both Human breast cancer and androgen-dependent prostate cancer cells. 2010; 4(24):632.
    9. Nguyen V, Tang J, Oroudjev E, Lee CJ, Marasigan C, Wilson L, Ayoub G.J Med Food. Cytotoxic effects of bilberry extract on MCF7-GFP-tubulin breast cancer cells. 2010; 2(13):278-85.